{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:51:51Z","timestamp":1792709511660,"version":"4.5.0"},"reference-count":18,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T00:00:00Z","timestamp":1643155200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Objective<\/jats:title>\n<jats:p>The aim of this retrospective observational study is to analyse clinical, serological and radiological predictors of outcome in patients with COVID-19 pneumonia treated with tocilizumab, providing clinical guidance to its use in real-life.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Method<\/jats:title>\n<jats:p>This is a retrospective, monocentric observational cohort study. All consecutive patients hospitalized between February the 11<jats:sup>th<\/jats:sup> and April 14<jats:sup>th<\/jats:sup> 2020 for severe COVID-19 pneumonia at Reggio Emilia AUSL and treated with tocilizumab were enrolled. The patient\u2019s clinical status was recorded every day using the WHO ordinal scale for clinical improvement. Response to treatment was defined as an improvement of one point (from the status at the beginning of tocilizumab treatment) during the follow-up on this scale. Bivariate association of main patients\u2019 characteristics with outcomes was explored by descriptive statistics and Fisher or Kruskal Wallis tests (respectively for qualitative or quantitative variables). Each clinically significant predictor was checked by a loglikelihood ratio test (in univariate logistic models for each of the considered outcomes) against the null model.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 173 patients were included. Only hypertension, the use of angiotensin-converting enzyme inhibitors, PaO<jats:sub>2<\/jats:sub>\/FiO<jats:sub>2<\/jats:sub>, respiratory rate and C-reactive protein were selected for the multivariate analysis. In the multivariable model, none of them was significantly associated with response.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Evaluating a large number of clinical variables, our study did not find new predictors of outcome in COVID19 patients treated with tocilizumab. Further studies are needed to investigate the use of tocilizumab in COVID-19 and to better identify clinical phenotypes which could benefit from this treatment.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0262908","type":"journal-article","created":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T18:34:07Z","timestamp":1643222047000},"page":"e0262908","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Predictive factors of clinical outcomes in patients with COVID-19 treated with tocilizumab: A monocentric retrospective analysis"],"prefix":"10.1371","volume":"17","author":[{"given":"Giulia","family":"Cassone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9948-652X","authenticated-orcid":true,"given":"Giovanni","family":"Dolci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Besutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Braglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Pavone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romina","family":"Corsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Sampaolesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Iotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Teopompi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Massari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Ghidoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anaflorina","family":"Matei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8622-0439","authenticated-orcid":true,"given":"Stefania","family":"Croci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele Alberto","family":"Negri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Costantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Facciolongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Salvarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,1,26]]},"reference":[{"key":"pone.0262908.ref001","doi-asserted-by":"crossref","first-page":"105954","DOI":"10.1016\/j.ijantimicag.2020.105954","article-title":"The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality","author":"C Zhang","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"pone.0262908.ref002","article-title":"Tocilizumab in patients with severe COVID-19: a retrospective cohort study","author":"G Guaraldi","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"pone.0262908.ref003","first-page":"98","article-title":"TOCIVID-19\u2014A multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia","author":"MC Piccirillo","year":"2020","journal-title":"Study protocol. Contemp Clin Trials"},{"key":"pone.0262908.ref004","article-title":"Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial","author":"C Salvarani","year":"2020","journal-title":"JAMA Intern Med"},{"key":"pone.0262908.ref005","article-title":"Efficacy of Tocilizumab in Patients Hospitalized with Covid-19","author":"JH Stone","year":"2020","journal-title":"N Engl J Med"},{"key":"pone.0262908.ref006","article-title":"Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial","author":"O Hermine","year":"2020","journal-title":"JAMA Intern Med"},{"key":"pone.0262908.ref007","article-title":"Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia","author":"C Salama","year":"2020","journal-title":"N Engl J Med"},{"key":"pone.0262908.ref008","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19","volume":"384","author":"TR-C Investigators","year":"2021","journal-title":"N Engl J Med"},{"key":"pone.0262908.ref009","first-page":"2021.02.11.21249258","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial","author":"PW Horby","year":"2021","journal-title":"Lancet"},{"key":"pone.0262908.ref010","article-title":"[COVID-19: Still a place for tocilizumab?]","author":"Q Richier","year":"2020","journal-title":"La Rev Med interne"},{"key":"pone.0262908.ref011","doi-asserted-by":"crossref","first-page":"6818","DOI":"10.1007\/s00330-020-07050-x","article-title":"Accuracy of CT in a cohort of symptomatic patients with suspected COVID-19 pneumonia during the outbreak peak in Italy","volume":"30","author":"G Besutti","year":"2020","journal-title":"Eur Radiol"},{"key":"pone.0262908.ref012","first-page":"201433","article-title":"Well-aerated Lung on Admitting Chest CT to Predict Adverse Outcome in COVID-19 Pneumonia","author":"D Colombi","year":"2020","journal-title":"Radiology"},{"key":"pone.0262908.ref013","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"C Huang","year":"2020","journal-title":"Lancet (London, England)"},{"key":"pone.0262908.ref014","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","author":"P Gautret","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"pone.0262908.ref015","first-page":"ciaa237","article-title":"In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)","author":"X Yao","year":"2020","journal-title":"Clin Infect Dis"},{"key":"pone.0262908.ref016","unstructured":"National Society of Infectious Diseases\u2019 (SIMIT) Guidelines for the managment of COVID-19 infection. Available at: http:\/\/www.simit.org\/medias\/1569-covid19-vademecum-13-03-202.pdf Last access April 5th 2020. No Title."},{"key":"pone.0262908.ref017","first-page":"1215","article-title":"Acute-phase reactants during tocilizumab therapy for severe COVID-19 pneumonia","volume":"38","author":"G Cassone","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"pone.0262908.ref018","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s11906-020-01101-w","article-title":"Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities","volume":"22","author":"D Patoulias","year":"2020","journal-title":"Curr Hypertens Rep"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0262908","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T18:34:24Z","timestamp":1643222064000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0262908"}},"subtitle":[],"editor":[{"given":"Tai-Heng","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,1,26]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0262908","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,26]]}}}